Literature DB >> 11163475

Strategies of immunization against mucosal infections.

M W Russell1, M H Martin, H Y Wu, S K Hollingshead, Z Moldoveanu, J Mestecky.   

Abstract

The presence of secretory (S-) IgA in middle-ear fluid and localization of IgA-secreting cells in its mucosae suggest that the middle ear is an effector site of the mucosal immune system. Several strategies have been devised to induce potent, long-lasting, and recallable mucosal S-IgA antibodies, as well as circulating IgG antibodies and Th1- or Th2-type help, according to the most appropriate responses for a particular infection. Application of immunogens to inductive sites in the upper respiratory tract may be most effective for generating responses in the middle ear and nasopharynx for protection against the organisms responsible for otitis media.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11163475     DOI: 10.1016/s0264-410x(00)00290-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

Review 1.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 2.  Identification and characterization of gonococcal iron transport systems as potential vaccine antigens.

Authors:  C N Cornelissen
Journal:  Future Microbiol       Date:  2008-06       Impact factor: 3.165

3.  Bacterial biofilm in upper respiratory tract infections.

Authors:  David P Morris
Journal:  Curr Infect Dis Rep       Date:  2007-05       Impact factor: 3.725

4.  CD4 T cell depletion at the cervix during HIV infection is associated with accumulation of terminally differentiated T cells.

Authors:  P P Gumbi; S Z Jaumdally; A L Salkinder; W A Burgers; N N Mkhize; W Hanekom; D Coetzee; A Williamson; J S Passmore
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

Review 5.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

6.  Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.

Authors:  Toru Takimoto; Julia L Hurwitz; Chris Coleclough; Cecilia Prouser; Sateesh Krishnamurthy; Xiaoyan Zhan; Kelli Boyd; Ruth A Scroggs; Brita Brown; Yoshiyuki Nagai; Allen Portner; Karen S Slobod
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.